A large global pharmaceutical company wanted to better understand the product potential of a late-stage, highly targeted pipeline drug candidate for immunotherapy. This drug was indicated for a complex, underserved therapeutic condition.

Viscadia was asked to design and build a custom forecast model spanning all global regions and accommodating key therapeutic and commercial drivers of product performance.